ACARIZAX (Seqirus Pty Ltd)
Product name
ACARIZAX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
205 working days (255)
Active ingredients
American house dust mite extract, European house dust mite extract
Registration type
EOI
Indication
ACARIZAX (tablets) is now also indicated for the treatment of house dust mite (HDM) allergic rhinitis not well controlled despite use of symptom relieving medication in adults and adolescents (age; 12 years).